A comparative 2-year study of the effects of sequential regimens of 1 mg 17β-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women

Gynecological Endocrinology

Volumn 21, Issue 2, 2005, Pages 82-89

  Koninckx, P R ^a   Spielmann, D ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Searle European Clinical R and D   (France)

Author keywords

Bleeding profile; Endometrial safety; Estradiol; Menopause; Norethisterone; Sequential combined hormone replacement therapy; Trimegestone

Indexed keywords

ESTRADIOL; ESTRADIOL VALERATE PLUS NORETHISTERONE; GESTAGEN; TRIMEGESTONE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; MULTICENTER STUDY; OVARY ADENOCARCINOMA; PAPILLARY CARCINOMA; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SPOTTING;

ADMINISTRATION, ORAL; ADULT; BODY WEIGHT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; PROMEGESTONE; PROSPECTIVE STUDIES; UTERINE HEMORRHAGE;

EID: 25144467816     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500168472     Document Type: Article

References (18)

1. Schiff I, Sela HK, Cramer D, Tulchinsky D, Ryan KJ. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 1982;37:79-82.
2. Harlap S. The benefits and risks of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol 1992;166:1986-1992.
3. Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 1999;13:316-326.
4. Weiderpass E, Adami H-O, Baron JA, Magnusson C, Bergström R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-1137.
5. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-1116.
6. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJB. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:1599-1605.
7. Beresford SAA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-461.
8. Whitehead MI. Prevention of endometrial abnormalities. Acta Obstet Gynecol Scand Suppl 1986;134:81-91.
9. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213-1223.
10. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-375.
11. Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2000;CD000402.
12. Granberg S, Wikland M, Karlsson B, Norstrom A, Friberg L-G. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991;164:47-52.
13. Pornel B, Spielmann D, Trimegestone 302 Study Group. A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17β-estradiol and trimegestone compared with a regimen containing 1 mg estraiol valerate and norethisterone over a 2-year period. Gynecol Endocrinol 2005;21(2):74-81.
14. Nasri MN CGJ. Correlation of ultrasound findings and endometrial histopathology in postmenopausal women. Br J Obstet Gynaecol 1989;96:1333-1338.
15. Committee for Proprietary Medicinal Products. Points to consider on hormone replacement therapy. London: European Agency for the Evaluation of Medicinal Products; 1997.
16. Archer DF, Pickar JH, Bottiglioni F, for the Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994;83:686-692.
17. Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001;8:245-251.
18. Erkkola R, Kumento U, Lehmuskoski S, Mattila L, Mustonen M. No increased risk of endometrial hyperplasia with fixed long-cycle oestrogen-progestogen therapy after five years. J Br Menopause Soc 2004;10:9-13.